TheraRadar
Data updated: May 26, 2026

WINLEVI (clascoterone)

Androgen Receptor Antagonists
First-in-Class
Dermatology Approved 2020-08-26

Winlevi is a topical cream that treats acne vulgaris in adults and adolescents 12 years of age and older. It helps patients with this skin condition by functioning as an androgen receptor inhibitor. This medication is used to manage common acne through direct application to the skin.

Source: FDA Label • Sun Pharma • Androgen Receptor Inhibitor

How WINLEVI Works

Clascoterone works by inhibiting androgen receptors. While the specific process by which this action improves acne is currently unknown, the drug functions as a localized androgen receptor inhibitor.

1
Indication
--
Phase 3 Trials
5
Years on Market

Details

Status
Prescription
First Approved
2020-08-26
Patent Cliff
2030

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
TOPICAL
Dosage Forms
CREAM

Companies

Active Ingredient: CLASCOTERONE

WINLEVI Approval History

2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2020 to 2022
Mar 2022 SUPPL
Label · Labeling
Aug 2021 SUPPL
Update · Supplement
Aug 2020 ORIGINAL
New Drug · Type 1 - New Molecular Entity

What WINLEVI Treats

1 indications

WINLEVI is approved for 1 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Acne Vulgaris
Source: FDA Label

WINLEVI Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to WINLEVI

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACANYA
BENZOYL PEROXIDE
1 shared
BAUSCH
Shared indications:
ACZONE
DAPSONE
1 shared
ALMIRALL
Shared indications:
ADAPALENE AND BENZOYL PEROXIDE
ADAPALENE
1 shared
PADAGIS ISRAEL
Shared indications:
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT06403501 LWY23090C Ph 3 recruiting Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

WINLEVI FDA Label Details

Indications & Usage

FDA Label (PDF)

WINLEVI is indicated for the treatment of Acne Vulgaris.

View full patent landscape →
8 OB patents · 2 families · 139 international docs across 30 countries

WINLEVI Patents & Exclusivity

Latest Patent: Jul 2030

Patents (8 active)

US8785427 Expires Jul 25, 2030
US9433628 Expires Feb 28, 2029
US11207332 Expires Nov 20, 2028
US10159682 Expires Aug 14, 2028
US12337002 Expires Jul 24, 2028
US9486458 Expires Jul 24, 2028
US11938141 Expires Jul 24, 2028
US8143240 Expires Jan 12, 2027
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for WINLEVI

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2030
  • 8 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 20 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.